Best of 2024 SABCS – San Antonio Breast Cancer Symposium
The SABCS 2024 (San Antonio Breast Cancer Symposium) took place from December 10th to 13th, 2024 at the Henry B. Gonzalez Convention Center in San Antonio, TX, USA.
The San Antonio Breast Cancer Symposium (SABCS) is an annual conference focused on the latest advancements in breast cancer research, treatment, and care.
This year, more than 11,000 individuals attended either in-person or virtually, setting an all-time record for the event. They were able to experience remarkable presentations, including clinical trial studies on promising drugs that may soon be available for use in clinics.
SABCS 2025 is scheduled for December 9-12, 2025, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
Healthcare Professionals and Organizations shared about this Conference on Social Media:
“Sarah McLaughlin, Yvonne Florance, Stephanie Wong, and Atif Khan discussed ‘Optimizing Local Therapy’ in an SABCS24 educational session moderated by Tari King.”
“Spent 90 mins on the SABCS24 stage yesterday, interjecting the advocacy perspective in “From the Trenches.” My words but it was these voices, and so many others not pictured, that I channeled. Grateful to have them by my side literally and figuratively to learn with, and from.”
“Impressive results from a randomized trial of neoadjuvant SHR-A1811 x8 (aka T-DXd cousin) +/- pyrotinib vs TCHP for mostly stage III HER2+ eBC. Comparable pCR rates across arms. Bodes well for DB11, though key differences in the dose and trial design may have relevant impact.”
“Excellent discussion by Aleix Prat Precision Oncology on 1L treatment approaches in HER2+ BC and if there is a role of ADCs in preop HER2+ dz More work ongoing for ADCs in 1L mHER2+ BC(DB09) and for preop HER2 + disease (DB11).
“It was a pleasure to watch AACR Board Member Christina Curtis deliver her AACR Outstanding Breast Cancer Investigator Award lecture. We thank BCRF Cure for supporting this award, which honors Christina for advancing our knowledge of the molecular determinants of breast cancer.”
“A randomized, placebo-controlled trial in people with early breast cancer of FORT (cognitive-existential fear of recurrence therapy, given twice wkly x 6 wks) found that FORT decreased fear of BC recurrence both post-therapy and 3 mos later.”
“Great presentation by Dr Maria Karsten from Germany presenting results of the ProB study + discussion by Gabrielle Rocque. We have enough evidence that remote symptom monitoring is useful for patients. Why are we still not using it widely?”
“Looking forward to SABCS24 General Session 1 – important updates for BRCA carriers:
– Super prof. Matteo Lambertini will present results on the role of risk-reducing surgeries on survival in young patients
– OlympiA updates.”
“Brilliant questions from Ellen Landsberger – could we use ctDNA here? Right now NO surveillance tests are done based on studies showing no improvement in OS but the studies that led to this recommendation were done DECADES ago, with X-rays and ultrasound.”
“Well, it only took us [Insert indistinct grumbling about how long we have been coming to San Antonio] years to visit the Alamo—but look—we finally remembered! —with Kevin Kalinsky and Seth Wander.”
“It was wonderful to discuss about novel treatment options for ER+ Her-2 Negative.”
“SOLTI Valentine: HER3-DXd +/- ET or Chemo in HR+/HER2- high risk EBC.
pCR rates similar.
Yet, it’s a randomised noncomparative trial…is it legit to compare?
HER3-DXd is effective. IMO, we’ll need better EFS (or better QoL) for routine use (after a bigger trial).”
“Day 2 Highlights Community Oncology:
1. EMBER3: Oral SERD in HR+
2. OlympiA: PARPi in gBRCA
3. Surgery in gBRCA
1. EMBER3: Ph III, Imlunestrant +/- Abemaciclib in HR+ advanced BC – Komal Jhaveri
– Imlunestrant alone for mESR1(mPFS: 5.5mos vs 3.8mos)
– Combo mPFS with all comers (9.4mos vs 5.5mos), regardless of CDK4/6 exposure
– If co-PIK3CA, Capi or this combo?
2. OlympiA: Update, Ph III, Olaparib in mBRCA HER2 -ve, EBC, high-risk s/p local Rx + neo or adj chemo, at 6yrs:
– iDFS by 9.4% & DDFS by 7.8%
– mOS by 4.4% (87.5% vs 83.2%), HR: 0.72
– Remains the current SoC in this patient population
Risk Reduction surgery in young BRCA carriers: <40 years old with Stage I-III breast cancer undergoing Risk-reducing mastectomy (RRM) and salpingo-oophorectomy (RRSO)
– RRM and/or RRSO associated with/ better OS
– RRSO benefit more pronounced with BRCA1.”
“Future Directions in Antibody Drug Conjugates: John Lambert, Giuseppe Curigliano, Ingrid Mayer, and Paolo Tarantino addressed this topic in the SABCS24 People’s Choice Educational Session.”
“Proud to be part of this important study on CDK4/6 inhibitor preferences in Latin America. Grateful for the opportunity to collaborate and contribute to improving breast cancer care.”
“Discussing the SABCS24 practice changing studies with global breast cancer expert and my former chairman Dr. Jame Abraham. Love his passion!!”
“PATINA SABCS2024
– Patients have gotten through a tough chemo, if you add something toxic to their subsequent therapy, it should increase OS!
– We NEED to stop saying toxicities are “manageable”, the palbo group had much more toxicities, it should be said like that, without spin.”
“Inspiring discussion on RCTs for interception using MUC1 antigen in premalignant lesions by Dr. Olivera Finn.
Key RCTSs:
Interception of DCIS
Prevention of colon cancer
TERT immuno-interception in BRCA1/2 carriers.”
“Excellent discussion by Giampaolo Bianchini at SABCS24 on the differences between Keynote 522 and GeparDouze outcomes! More research is needed to move beyond the Keynote 522 regimen with both deescalating and escalating approaches.”
“Thank you for mentoring!! A Giant mentor Fabrice Andre at Gustave Roussy with Toshimi Takano.”
“Great panel on case based discussion on ER positive breast cancer! Daniel Stover presenting data on ctDNA and clinical utility in MBC!”
“Helpful summary on partial breast irradiation by Dr. Atif Khan including his thoughts on PBI now that we’re considering SLNB omission.”
“‘EMBER-3 Trial Results’
Imlunestrant improved PFS in HR+/HER2- mBC with ESR1 mutations: 5.5 vs 3.8 months(vs standard endocrine therapy).
Adding abemaciclib boosted PFS in all patients: 9.4 vs 5.5 months (43% low progression/death).
Fewer risks of bradycardia, high cholesterol, and visual issues vs other SERDs.”
“What to do here? Current SOC is endocrine therapy + CDK4/6 inhibitor but SONIA showed that endocrine therapy alone may be just as good, adding a CDK4/6i later with progression – and preserves QOL better, including lessening financial toxicity.”
“How to treat her2 postive MBC at the end of 2024. Money slide. note the foot note for patina data.”
“Super discussion by Giampaolo Bianchini at SABCS24 on the NSABP Foundation B-59/GBG-96 GeparDouze and CamRelief trials assessing neoadjuvant immunotherapy in early triple-negative Breast Cancer.”
“Educational Session 8: Optimizing
Local Therapy
Topic 2: Axillary Management: When to Dissect and When to Radiate by Stephanie Wong.”
“Great panel discussion regarding importance of communication with patients during treatment planning. To make the best decisions we need to educate patients, empowering them to make informed decisions, says Amy Beumer. So much to consider!”
“New work on a cell atlas of normal breast tissue may facilitate the early prediction and even prevention of breast cancer. This new resource will be the focus of the second Plenary Lecture Friday morning at SABCS24. Learn more in SABCS Meeting News.”
“One of the most brilliant discussant at SABCS24, Giampaolo Bianchini.
Don’t miss the opportunity to treat ER low (1-9%) with chemo plus pembrolizumab with a pCR rate similar to TNBC.”
“Fantastic ER+ Breast Cancer summary and algorithm by Dr. Danso at year in review.
First line CDK
2nd line profile driven
ADC/chemo once endo-R!”
“Awesome to get to chat with Josh Drago for a SABCS24 snippet on the past, present and future of ADCs. Huge growth in the field, paralleled by many efforts to make ADCs more targeted, safer and personalized based on novel biomarkers. Thanks SABCS for having us!”
“SABCS24 Year in Review – Advanced Breast CancerUpdates by Michael Danso
Highlighting key advancements in advanced breast cancer research and treatment from the past year.”
“Following up with a few resources from FDA-Alamo Breast Cancer session today for breast cancer advocacy community
Someone asked for email to report misleading drug ads: [email protected]
There were sev Qs from breast cancer advocacy community re new laws you want to see. That’s Congress you need, and here’s how you reach the switchboard! As you see, I have them as a Fave. They’ll connect you to your elected officials.
Many advocates asked where to learn more about their meds. The drug label is a great source of info and most current version is always here. You can search by name. Misplace this tweet? Just Google “drugs@FDA
Bready Cancer advocacy, here you’ll find a succinct summary of basis of FDA approval for breast cancer (& other cancer) meds, esp those recently FDA-approved.
(Also great for busy clinicians and Board review). Bookmark!
Finally, if you have Qs about compassionateuse of investigational agents (not only cancer) because you can’t access clinical trials, the Regan-Udall Expanded Access Navigator is a huge help! Check it out.”
“Also this year I can confirm that SABCS is my fav congress of the year.
I am so proud to have received an Early Investigator Award for the study we presented today, and to share this achievement with the entire team of wonderful colleagues and friends!”
“Does Postmastectomy Radiotherapy in ‘Intermediate-Risk’ Breast Cancer Impact Overall Survival?
The answer is no, though the grey area is still there.
10-Year Results of the BIG 2-04 MRC SUPREMO Trial presented by Ian Kunkler.”
“Project Life so happy to play a small role with these amazing leaders and visionaries.”
“Pt Advocate, co-founder GRASP Christine Hodgdon brings patient perspectives to Educational Session 12 SABCS. And, a msg to researchers: “you do not need to tackle the complexities of research alone, plenty of advocates willing to collaborate!”
“Hengrui’s Camrelizumab vs Placebo With Chemotherapy as Neoadjuvant Treatment in TNBC (CamRelief) – actually perioperative.
CamRelief KM plots SABCS24.
– EFS (time from randomization to disease progression, recurrence, or death from any cause)
– DFS (time from surgical procedure to disease recurrence, second primary tumor, ductal carcinoma in situ, or death from any cause)
– DDFS (time from surgical procedure to distant metastases or death from any cause)
Neoadjuvant Camrelizumab for Triple-Negative Breast Cancer.”
“Impressive results from the Ember-3 study. I would like to see the number of grade 2 diarrhoea in the Imlunestrant + Abemaciclib arm.
Remember: Grade 2 AEs matter to patients!”
“SABCS24 meta analysis report: Overweight, Obesity and Prognosis in 206,904 Women in the EBCTCG Database presented by Hongchao Pan.”
“Practice-changing findings from SABCS24! The PATINA trial reveals improved progression-free survival in HR+/HER2+ metastatic breast cancer with palbociclib added to endocrine and anti-HER2 therapy. Join me and Moffitt Cancer Center’ Tracey O’Connor, MD, to break it all down.”
“SABCS24 came to its end, and I bring home great memories:
– my first Early Investigator Award
– seeing presented at the General Session (by Matteo Lambertini) new results of our collaborative BRCA BCY group
– Love to all the amazing friends with whom I share this journey.”
“CamRelief, early TNBC, NACT +/- periop Camrelizumab (SABCS24):
– Cape allowed.
– pCR rate improved (12% delta).
– No EFS benefit yet (immature).
Looking similar to GeparDouze. Diff with KN522 a question of anti-PD-1 vs anti-PD-L1, or cape being permitted? Both? Asian patients?”
“My take aways from SABCS24: anthra beneficial for RS>31; imlunestrant active as single agent unclear what combo data means; Pablo gives excellent benefit in triple pos bc; please don’t use MRD ; brca + bc pts have benefit from rrbm; and tons of important data on local therapy.”
“Wrapping up another fantastic SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!”
“SABCS24 is over and once again my cup is filled by the science, but even more from the connections with oncologist, researcher, and advocate friends. See you in 2025 (if I’m still Not Dead Yet).”
“SABCS24 is a wrap! Thanks to the co-directors, executive committee, program planning committee, speakers, and attendees for making this year’s Symposium a spectacular success.”
Further Reading:
Highlights from Day 1 of SABCS 2024
Highlights from Day 2 of SABCS 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023